Molecular Partners Class Action Lawsuit MOLN | Deadline September 12, 2022

Announcement! The MOLN Lawsuit is open to all investors who purchased or otherwise acquired Molecular Partners AG (Molecular Partners Class Action Lawsuit) securities between June 16, 2021, and April 26, 2022.

FOR MORE INFORMATION ON THE MOLN CLASS ACTION LAWSUIT, CLICK HERE

According to the MOLN lawsuit, the defendants allegedly made the following claims during the Class Period and/or omitted to disclose them:

(i) Ensovibep, a product of the company, was not as successful at treating COVID-19 as the defendants had misled investors;

(ii) as a result, the U.S. Before approving ensovibep for emergency use, the Food and Drug Administration (FDA) was a reasonable candidate to demand an extra Phase 3 investigation of the medication;

(iii) declining global COVID-19 rates greatly decreased the Company’s chances of obtaining an EUA for ensovibep;

(iv) Molecular Partners’ partner, Amgen, was less interested in the Company’s MP0310 product candidate than the defendants had misled investors about;

(v) Consequently, there was a high probability that Amgen will transfer the worldwide rights to MP0310 to Molecular Partners;

(vi) Due to everything described above, ensovibep and MP0310’s clinical and business potential were exaggerated; and

(vii) Due to this, information required to be included in certain documents issued in connection with the Company’s initial public offering and the defendants’ public comments made during the class period were both materially false and/or misleading.

You have until September 12, 2022, if you suffered a loss in the MOLN Lawsuit, to ask the court to name you as the lead plaintiff. You are not required to act as the main plaintiff in order to share in any recovery.